Skip to main content

Table 1 Patient characteristics

From: Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

 

All patients (n = 660)

Unmatched (n = 349)

 

Matched (n = 224)a

 

C20

C25

SD score

C20

C25

SD score

N

660

190

159

112

112

Age, years

70.0 (43–91)

71.0 (51–89)

69.0 (44–83)

0.271

69.5 (51–89)

70.0 (51–83)

0.051

Body surface area, m2

1.65 (1.26–2.20)

1.63 (1.26–2.02)

1.65 (1.30–2.20)

0.046

1.66 (1.26–2.02)

1.66 (1.30–2.20)

0.016

Duration of disease, years

4.16 (0.5–19.8)

4.71 (1.0–17.5)

3.85 (0.8–19.8)

0.059

4.10 (1.0–17.5)

3.71 (0.8–19.8)

0.069

Gleason score

2–7

104 (15.8)

28 (14.7)

27 (17.0)

0.064

14 (12.5)

15 (13.4)

0.025

 

8–10

516 (78.2)

149 (78.4)

125 (78.6)

98 (87.5)

97 (86.6)

 

TNM stage

T1 + T2

113 (17.1)

37 (19.5)

30 (18.9)

0.013

20 (17.9)

22 (19.6)

0.045

 

T3 + T4 + TX

538 (81.5)

149 (78.4)

128 (80.5)

92 (82.1)

90 (80.4)

 
 

N0

297 (45.0)

94 (49.5)

72 (45.3)

0.068

50 (44.6)

53 (47.3)

0.054

 

N1 + NX

359 (54.4)

93 (49.0)

86 (54.1)

62 (55.4)

59 (52.7)

 

M0

190 (28.8)

58 (30.5)

45 (28.3)

0.054

32 (28.6)

30 (26.8)

0.040

 

M1 + MX

466 (70.6)

131 (69.0)

112 (70.4)

80 (71.4)

82 (73.2)

ECOG PS

0

412 (62.4)

109 (57.4)

100 (62.9)

0.126

68 (60.7)

67 (59.8)

0.018

 

≥1

247 (37.4)

81 (42.6)

58 (36.5)

44 (39.3)

45 (40.2)

PSA (at baseline), ng/mL

164.9 (0.0–16,697.2)

146.1 (0.0–10,027.1)

173.2 (0.3–9892.3)

0.110

120.8 (0.0–4286.0)

187.6 (0.3–9892.3)

0.068

Previous medical history

202 (30.61)

65 (34.2)

44 (27.7)

0.159

36 (32.1)

37 (33.0)

0.019

Complications

275 (41.67)

82 (43.2)

61 (38.4)

0.146

42 (37.5)

43 (38.4)

0.018

Previous treatments

Radical local excision

212 (32.12)

62 (32.6)

49 (30.8)

0.061

31 (27.7)

33 (29.5)

0.039

Switch from docetaxel

114 (17.27)

38 (20.0)

26 (16.4)

0.172

21 (18.8)

21 (18.8)

0.000

New-generation AR inhibitorsb

 0 or 1 agents

340 (51.5)

96 (50.5)

89 (56.0)

0.010

60 (53.6)

59 (52.7)

0.018

 2 agents

319 (48.3)

94 (49.5)

70 (44.0)

52 (46.4)

53 (47.3)

Docetaxel chemotherapy

630 (95.5)

186 (97.9)

154 (96.9)

0.070

112 (100)

112 (100)

0.086

Docetaxel treatment cycles

9.0 (1–143)

9.5 (1–47)

9.0 (1–52)

10.0 (1–47)

8.0 (1–38)

Reason for discontinuing docetaxel

PD

534 (80.9)

161 (84.7)

130 (81.8)

0.085

93 (83.0)

92 (82.1)

0.024

AE/other

108 (16.4)

29 (15.3)

26 (16.4)

19 (17.0)

20 (17.9)

Palliative radiation therapy

197 (29.8)

69 (36.3)

47 (29.6)

0.182

36 (32.1)

34 (30.4)

0.038

  1. Values are reported as the median (range) or n (%)
  2. C20 20 mg/m2 cabazitaxel, C25 25 mg/m2 cabazitaxel, SDscore, standardized difference score, TNM Tumor-node-metastasis, ECOG PS Eastern Cooperative Oncology Group performance status, PSA Prostate-specific antigen, AR Androgen receptor, PD Progressive disease, AE Adverse event
  3. aPatients were matched using propensity scores on 17 factors: age, body surface area, duration of disease, Gleason score, T classification, N classification, M classification, ECOG PS, PSA, medical history, complications, curative intent focal therapy, palliative radiation therapy, switch from docetaxel, number of docetaxel treatment cycles, reason for discontinuation of docetaxel, and previous treatment with enzalutamide or abiraterone
  4. bEnzalutamide or abiraterone acetate